Fertility benefits platform developer Progyny has raised $10m from investors including SR One to increase its series B round to $24.7m.

SR One, the corporate venturing vehicle for pharmaceutical firm GlaxoSmithKline, has helped US-based fertility benefits platform Progyny add $10m to a series B round now sized at $24.7m.

The extra funding was provided by all the company’s existing investors, with Kleiner Perkins Caufield and Byers (KPCB) and TPG Biotech co-leading the tranche with Progyny.

Reproductive health technology companies Auxogyn and Fertility Authority merged in 2015 to form Progyny, which provides fertility benefits services to self-insured employers that helps improve…